ArticleHealth science reports2025
The Use of Extracellular Vesicles as a Promising Therapeutic Approach for Pulmonary Diseases.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extracellular vesicles in senescence-associated chronic lung diseases.Chinese medical journal · 2026Review
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Cell-specific exosomes in sepsis-associated ARDS: from immunometabolic reprogramming to precision medicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Pulmonary disorders significantly impact worldwide healthcare, highlighting the necessity for enhanced diagnostic and treatment approaches. This narrative review seeks to investigate the potential of extracellular vesicles (EVs) as an innovative therapeutic strategy for diverse pulmonary disorders. Methods: This review synthesizes existing data about the function of extracellular vesicles (EVs) in pulmonary health and pathology, emphasizing their modes of action, including the transfer of proteins, nucleic acids, and lipids for intercellular communication. It also examines the implications of EVs in targeted medication delivery, immunomodulation, and tissue regeneration. Results: EVs, including microvesicles and exosomes, have demonstrated promise in treating respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Additionally, EVs may serve as valuable biomarkers for early disease detection, prognosis, and monitoring. However, challenges remain regarding the standardization of EV isolation methods and characterization protocols to ensure safety and clinical applicability. Conclusion: In summary, extracellular vesicles hold potential for transforming the management of pulmonary diseases by providing insights into pathophysiology, enabling early diagnosis, and facilitating personalized treatment approaches. Further exploration of EV-based therapies is necessary to fully realize their potential in improving outcomes for lung disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.